Information Not Available

Information Not Available

Hypernatraemia, thirst, reduced salivation and lachrymation, fever, tachycardia, hypertension, headache, dizziness, restlessness, irritability and weakness. Intra-amniotic inj of hypertonic solutions: Disseminated intravascular coagulation, renal necrosis, cervical and uterine lesions, pulmonary embolism, pneumonia and death.

Hypertension, heart failure, peripheral or pulmonary oedema, impaired renal function, liver cirrhosis, preeclampsia. Maintain adequate water intake.

Pregnancy: Inj of 3 or 5% NaCl solution should be given through a large vein at a rate not exceeding 100ml/hr. Monitor fluid balance, serum electrolytes and acid base balance especially during prolonged treatment. Caution when used in patients who are receiving corticosteroids or corticotropin.

Drug Interactions
Additives may be incompatible. Consult with pharmacist, if available. When introducing additives, use aseptic technique, mix thoroughly and do not store.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution container permits.

May affect serum concentrations of lithium

Nasal congesation:
Adult: 0.9% used as nasal drops or spray.
Child: 0.9% as nasal drops.

Information Not Available

Teratogenic Effects
Pregnancy Category C. Animal reproduction studies have not been conducted with Sodium Chloride Irrigation, USP. It is also not known whether Sodium Chloride Irrigation, USP can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Sodium Chloride Irrigation, USP should be given to a pregnant woman only if clearly needed.

Caution should be exercised when Sodium Chloride Irrigation, USP is administered to a nursing woman.

Safety and effectiveness of Sodium Chloride irrigation solution in pediatric patients have not been established by adequate and well-controlled trials. However, the use of Sodium Chloride irrigation solution in the pediatric population is referenced in the medical literature. The Warnings, Precautions, and Adverse Reactions identified in the label should be observed in the pediatric population.

An evaluation of current literature revealed no clinical experience identifying differences in response between elderly and younger patients.
This drug is known to be substantially secreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

Information Not Available

Information Not Available

Information Not Available